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From nciJ/eUumol c~lr~~rtd of bucgic~l spccinrcnx of human htrpe intestine WC iaalatad two pptidcs, in approximately equal amountr, thtrr. ~&led 
with an antiserum agninrt pereinc grlrnin. By amino acid analyxin, aqusncc analysis and mass apceerramerry, rhc ltupcr artha two pcptidcr was 
fkund to consist or 30 am;no ncid residues, the sequence or which wax idcnticul to Ihat af pureinc @min oxeepr Par rhc iWewiny substitutions: 
VtP, AIR”, AnrP, ThF and SC~‘~. Unlike poreinc galanin, the carbtxy+xminw was nor rmidutcd. The rmollcr pcprirlc c~~~sparrdcd ta the 
first 19 amino acid. rexielucw eaunrcd Cam the N-terminus ar the 30 residue peptide @grin without rmfdrtion), The strue~unl analysis WI% rcpcalcd 
em another batch of tissue with identical rcwultr. By HPLC analyris of extracts cat’ specimens rrom a Mhcr 4 patients, the sami! pcpridet wcro 
idcntificd. Thus, human gnlanin includes two pcptidcs of I9 and 38 amino acids that rbaro the sequence of the N-terminal I5 residues with other 
rntmmalirn ~alrninr. but exhibit charaetcriotic dift’eravzcn in rhc romair4ng part of rhc matceulcs, 
Prognlnnin; Pasttrunnlatianal processing; Neuropeptidc; Amidatcd peptide 
1. INTRODUCTION 
Galanin was originally identified as a ncuropcptide of 
29 amino acids in extracts of pig small intestine by the 
use of a chemical detection method [l]. Galanin4ike 
immunoreactiviry (GAL-LI) is ‘present in the central 
nervous system, the peripheral nervous system, pan- 
creas and adrenals [2]. 
Consistent with its widespread localization galanin 
controls various biological activities: it regulates growth 
hormone release, it contracts smooth muscle 
of the gastrointestinal and genitourinary tract, it 
modulates irisulin release and may be involved in 
the control of adrenal secretion [2,3]. By means of 
molecular biology techniques the structures of rat and 
bovine galanin have also been deduced [4,5]. 
The three animal forms are identical with respect o 
the first IS residues but differ at several positions in the 
C-terminal part.. The sequence of human galanin is not 
known, but the molecule does not react with antisera 
against the C-terminal region of porcine galanin, 
Correspondence uddress: J.J. Hoist, Institute of Medical Physiology 
C, The Panum Institute, Blegdamsvej 3c, DK-2200 Copenhagen N, 
Denmark. Fax: (45) (31) 35 7657 
Abbrevialions: GAL-LI, galanin-like immunoreactivity; HPLC, high 
performance liquid chromatography; ACN, acetonitrile; TFA, 
trifluoroacetic acid; HFBA, heptafluorobutyric a id; PTH, phenyl- 
thiohydantoin; PDMS, plasma desorption mass spectrometry 
Published by Elsevier Science Publishers B. V. 
indicating that also human galanin diFfers from its 
porcine counterpart in this region [al. 
This difference may have important functional impli- 
cations, Thus porcine galanin and rat galanin inhibit in- 
sulin secretion in rats and dogs, but has no effect on 
glucose-induced insulin secretion in man and augments 
insulin secretion from isolated perfused pig pancreas 
[9-g]. These results illustrate the importance of study- 
ing the effect of the regulatory peptides in the autolo- 
gous species. It is therefore essential that the structure 
of human galanin is known, allowing synthesis of the 
peptide and its subsequent use in functional studies. 
,Here we report the isolation and :structure of two, 
galanin immunorcactive forms from normal human 
colon. 
2. MATERIALS AND METHODS 
2.1. Guiunin radioitntttunoassuy 
In all purification steps GAL-L1 was monitored by radioimmuno-. 
assay based on a non-C-terminally directed antiserum (RAGS) 
produced in rabbits [lo]. Synthetic porcine galanin (Dachcm, 
Bubendorf, Switzerland) was used as standard and as tracer, labeled 
according to the rtoichiometric hloraminc-T method 691. The 
purification of the labeled material was performed as described [3]. 
Incubation conditions and separation were as described in [9], 
2.2. Extraction procedurti 
Pieces of normal human colon (14 specimens ofvarying sizes, SgO g 
total) were obtained uring surgery on the gastrointestinal tract (ap- 
proved by the Local Ethical Committee), cleaned from the fat and the 
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The lirxur extracts were subjcctcd to gel pcrmcntian rhramalo- 
grtrphy either on 50 x 1O@l mm (KSO/I#0) or on 16x I[K)Bmm 250 ’ $041 
#IQ/lOO~lass columns paekrd wirh Scphadcx C&SO fine grndc p.02 
(Pharmnrlrs, Uppmritl, Sweden), equilibrrlcd and dluretl wirh a.5 M 
weefic acid nt n plow rak, rcrpexivcly, of 1 tnl/tnin and 0.4 milmin. 
Trwc mounts of’ ‘a~i-labrled albumin and “NnCI wcrc added w all 
rsmplca prior 10 gel Tiltrarion t’ar inrcrnsl ealibration~ X;l, rhe coelfi- 
eicnt of distribution, war Ihcn colcuk~tcd for ail fractions using rhc 
0, .o .O 
cqualion: &-(V,- V,)/V whrrc V, is rhc clution volrlmc of ‘% ’ MINUTES 2o 40 
albumin, and fl the available inner volume of the column, detcrminsd 500’ 
RJ ~hc difference between thr cktion volumex of ‘3Nn and ‘rrl, Prar- 
ABS ACN 
lions comainlnp GAL-LI were then subjected to rcverscd phase PMOLlL 9.w C 
WPLC, separately for rhc initial run, then as a pool of roeluring 
fractions with GAL-U. The HPLC columnr were packed with 
Nuclcosil 300.7 jrrn CdHs, 120-7 brn CN, and 3004 cm C-18 
(Machcrey-Nagel, Duren, Germany) and elutcd (employing LKB 
250 - .SO% 
HPLC equipment) with gradients of varyin steepness of 
p,o2 
either acetonitrilc/wntcr/tritluoracctic acid (ACN/water/l’FA) 
(A, 0:99.9:0.1; and B, 99.9:0:0,1) or ncctonitrilf/water/l~c~~~a- 
fluorobutyric acid (ACN/wnter/HFBA) (A, 0:99.85:0,15; and 
B, 99.8S:O:O. 15) (ACN HPLC grade, Rnthburn, Walkerburn, 0. .o ..o 
Scotland) (TFA and HFBA from Pierce Europe BV, The Ncthcr- 
lands). The immunorcactivc material was chromatographcd with ’ MINUTES *’ 
40 
increasingly shallow gradients until two resulting immunoreactive FiB. I. isolation of GAL-LI frc;m human colon. The concentration 
pcptidcs seemed pure as judged by absorbance at 226 nm (Fig. I). The of GAL-LI was monitored by radioimmunoassay (Icft ordinate scale) 
final run was performed with ACN/watcr/HFBA gradients from 
30% to 36@70 of B in 30min for one form and from 28% to 34% of 
using a non-C-terminally directed antiserum, (A) Shows the IR profile 
at gel filtration: the concentration is plotted against &, the coeffi- 
B in 30 min for the other one. Prior to further analysis the purified cicnt of distribution, calculated as described in the text. In (B) and (C) 
pcptides were concentrated on a narrow-bore Vydac C8 column (code are shown the last reversed phase HFLC runs (on a Cl8 column) of 
no. 208TP5215, 2,l x IOOmm) at a flow rate of 2OO~tlmin using a the first and the second peak identified by thn gel filtration (the peaks 
Hewlett Packard HP IO90 system equipped with diode array detector, 
The absorbance was monitored at 214nm and the Bradient was 
were subsequently used for sequence determination and PDMS), The 
immunorcactivc ma:erial was 
ACN/water/TFA. 
eluted with a gradient of 
ACN/water/HFBA, The concentration of GAL-L] (in histograms) is 
2.4. UPLC idetrt(fkalion 
plotted against the percentage of acetonitrile (ACN, extreme right or- 
dinate scale) and the absorbance (ABS, on the right ordinate scale) ex- 
The extracts of 4 pieces of human colon were separately injected pressed in arbitrary units. 
(after addition of 10% ACN) onto a column with 300-5/rm C18 as sta- 
tionary phase and eluted with gradients as above. The retention times 
of the immunoreative components were then compared with those of derivatives (AI3 120A). For this chromatography a C-18 3/cm column 
the isolated forms. (5-7943, Supelco, PA, USA) was used. Solvents were those recom. 
mended by ABI (A: 16 mmol/ I NaAc, pi-l 4.0 in 5% tetrahydrofuran; 
2.5. Amino acid analysis El: 5 mmol/l dimethylphenylthiourea in acetonitrile). With this 
Analysis of 10% of the purified peptides was performed after column it was possible to completely separate Trp from the sequencer 
hydrolysis for 20 h in 6N HCl in gas phase at 110°C. The byproduct Ar,N ‘-diphenyl urea. 
hydrolysates were analyzed on ari Aminoquant system (Hewlett- 
Packard). Ail chemicals were analytical grade and all solvents were 2.7. Mass spectrotnelry (PDMS) 
HPLC-grade. Molecular mass determination \?yas carried out on a Bio-Ion Bin 
1OK plasma desorption time of flight mass spectrometer (Bio-Ion AB, 
2.6. Sequence analysis Uppsala, Sweden). Approximately 50 pmol of each peptidc were ap- 
The sequences of the purified peptides were determined on an plied to aluminized mylar foil coated with nitrocellulose in 2,4 of 
automatic protein sequencer (Model 475A, ABI (Applied Biosystems 0.1% TFA and dried as described in [ 121. After insertion of the sam- 
Instruments)) equipped with on-line HPLC detection for the PTI-I- pie in the mass spectrometer it was bombarded with fission fragments 
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50 pmd d (rcgriric (HX krlow), and rhr! rn&,tS or thr matlkl pcpM Ron WI-Q idcnricwt for the ditfercnt extract%, At 
&bxmlncd 8f &~ilrsd &w~~ filtration, tho GAC.=!J elutrd in two pcwks, one at 
nather at a,72 (Fig. I A). At the final HP&C 
run on zl Cl% aiupport and a shrllaw ACN/vr;srtert 
3. KEWJLTS HFBA ~radiens, the J%T~ = OSI form elutcd at 32% ACN 
nnd the 8% M 0.42 form at 30%9 ACN (Fig, IE,C), 
LniriatLy QOOg erF freshly obtained tissue was ex- The HPEC idcntiPication study of extraa prepared 
tracted, and peptidcs(n) with OALU were purified and freshly from four specimens of colon and directly 
further analyzed by amino acid sequencing, amino acid applied to HFbC revealed for al1 extracts two im- 
ana\ysis and PBMS. Because of the unexpected results munorcactive forms with retention timer chat were 
a further batch of 245 g of freshly obtained human identical to those of the two purified forms (not 
colan was submitted co the same procedure with iden- shown). 
ticnl results. The purified peptides were further studied by 
amino acid sequencing, amino acid analysis and mass 
Table I spectramerry, The form eluting at 32% ACN consisted of 30 amino 
Sctluencc mmlyai% of I;llc ynlrnln 18 peptides cluring at the reversed 
phase w Pbe: aI 32% nntl Moio of ACN 
acids, the scqucnce of which is shown in Table 1. The 
amino acid composition appears in Table II and the 
Yields are corrected for btisklgrounct ns well 8% l&1$. ln b0th pcptidcs PDMS spectrum in Fig. 2A. The presence of Trp was 
amine acid 2 was idcfitificd bark as gemin PTH-Trp end Ps w 
dcrivntive of Pfl-t.Trp that cturcd midway betweet N,N’-diphenyl- 
confirmed by the second derivative of the spectrum 
rhiounn and N,lln’~tllpRcnylurca. 
recorded during the concentration procedure of the 
sampte, showing a minimum at 290nm [14]# The 
Cyck PTfkicrivnrive 32% ACN form 30% ACN Form 
average mass of the peptide, 3157,grt3,2 DR, is in 
Y icld (pmol) Yield (pmol) 
agreement with the calculated theoretical value of 
3157.4 Da, Because the precision of the PDMS in this 
I GlY ICI6 181 
2 Trp 12 80 
mass range is insufficient o determine whether the pcp- 
3 Thr 151 2lH 
tide is COOH-terminally amidared or not, a sample was 
4 Lcu 86 %i methyl-esrerificd by a procedure which methylates all 
Asn 50 82 carboxyi groups (and thus add 14.02 atomic mass unit 
:, SW 83 150 for each) in the molecule [131. The resulting mass spec- 
7 Ala 63 91 
8 ‘JY 44 57 
trum (Fig, 2B) showed a methylated average mass of 
9 Tyr 60 54 
3 186.1 k 3,2 Da. This mass increase corresponds to two 
IO Leu 52 73 
11 LCU 51 66 
Tablc II 
I2 GlY 36 46 Amino acid analysis of the two human galanin forms, l-30 and l-19 
13 Pro 28 72 
14 MS 13 26 Fbr the analysis, 50 and 45 pmol, respectively, were hydrolyzed. Trp 
15 Ala 30 68 was not determined. 
16 Val 29 53 
17 GlY 21 29 
Number of Expected Galanin Expected Galanin 
Asn 10 45 residues: 
I-30 l-19 
-- 
1; His * 4 
20 
Aspartic acid 4 3.9 -2 
AU 12 
2.2 
Glutamic acid 0 0.2 0 0.5 
Wine 4 
21 Ser 
3.3 
29 
1.1 
22 
Mistidine 2 2.1 : 
Phe 23 
2,O 
Glycine 
23 
5 5.0 4 
SW 21 
43 
Threonine 2 1.7 1 
24 Asp 18 
1.1 
Alanine 2 1,9 2 
Lys 
2,O 
2 
:: 
Arginine 1 1.1 0 
Asn 
0.2 
5 Tyrosine 1 0.9 1 
27 GlY 
0.9 
7 Valine 1 1.0 I 
28 Lell 10 
1.3 
lsoleucine 
29 
0 0.1 0 
Thr 10 
0.2 
!@thionine 0 
30 
0.0 0 
SW 
0.1 
13 Phenylalanine I 1.0 0 0.5 
*Not found in this run due to injection failure, but His” was unam- 
Leucine 4 4.9 3 3.3 
biguously identified in a preliminary run on a smaller amount of pep- Lysine 
I 1.3 0 0.4 
tide, 
Proline 1 1.0 1 1.2 
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Fig, 2. (A) PDMS spectrum of intact human galanin l-30, Approximately 50 pmol was applied to a nitrocellulosc-covered aluminized mylar target, 
(B) PDMS spectrum of human galanin after methyl esterification. Both spectra have been background subtracted0 
methyl groups indicating the presencr of two non- 4. DISCUSSION 
derivacized carboxyl groups. When compared with the 
sequence (a single acidic side chain in addition to the C- Galanin was first isolated as a 29 amino acid residue 
terminal a-carboxyl group) it may be concluded that peptide from extracts of pig intestine by the use of a 
none of them are blocked, i.e. the peptide is not chemical method detecting amide groups [l]. The 
carboxy-amidated at its C-terminus. finding in the cDNA of rat and bovine species of a 
The peptide elucing at 30% ACN consisted of I9 signal for Gly in position 30 led to the assumption that, 
amino acids (Table II), the sequence of which is in general, galanin is a 29 amino acid residue, C- 
reported in Table I. From the PDMS spectrum (not terminally amidated peptide [4,5]. 
shown) an average mass of 1964.4 f 2.0 Da was obtain- By the use of a radioimmunoassay based on an anti- 
ed, in agreement with the calculated theoretical value of serum against he N-terminal part of porcine galanin we 
1964.2 Da for this peptide. By methyl esterification a now isolated two peptides with galanin-like immuno- 
single free carboxyl group was identified, i.e. the C- reactivity from extracts of human colon and determined 
terminal one (not shown). their primary structure. The two peptides consisted of 
19% 
30 and 19 amino acids and occurred in almost equal 
amounts as judged from the immunoreactive signal ob- 
rained by gel filtration and HPLC. Upon sequence 
analysis it turned out that the 19 amino acid peptide 
corresponded to the l-19 sequence of the larger pep- 
tide. The first IS amino acids of the peptides are iden- 
tical co those of the porcine, rat and bovine galanins, 
but several substitutions characterize the C-terminal 
part of the sequence (Fig. 3). Compared with porcine 
galanin there are changes at positions 16, 17,23, 26 and 
29. Surprisingly, the human galanin is not a 29 amino 
acid residue, C-terminally amidated pcptidc. It has a 
Ser in position 30, substituting the Gly that functions as 
an amide donor in the other species. The other variable 
amino acids occur at the same positions in all species 
and can be explained by single base substitutions for the 
changes at positions 16, 17,26,29 and 30; the change in 
23 is more extensive, involving two substitutions when 
the couples pig-man, pig-rat, cow-man and cow-rat 
are compared. A single base substitution characterizes 
the difference between pigs and cows at this position. 
The existence of more than one molecular form of 
galanin in humans was suspected from gel filtration 
studies by Bauer et al. [6], who also found close to equal 
amounts of the two forms. Our data show that the 
smaller form is identical to the 1-19 N-terminal frag- 
ment of the 30 amino acid peptide. A posttranslational 
processing of the precursor to give rise to this peptide 
could occur as an initial cleavage between residues 20 
and 21 (Arg and Ser), a mono-basic leavage, known to 
occtie in many peptide precursors [Is], followed by 
removal of Arg2’ by a carboxypeptidase-B-like mcchan- 
ism [IS]. 
Both the 19- and the 30-amino acid residue peptide 
may be biologically active. Structure/activity studies 
have shown that, although less potent than galanin 
l-29, N-terminal fragments of galanin as small as the 
I- 15 fragment may bind to the galanin receptors of rat 
brain and pancreatic islet tissue and to receptors of 
insulinoma cell. lines (16-19), and the l-20 fragment 
was reported to be cquipotent with full-length galanin 
with respect o the effect on intestinal motility in dogs 
[20]. On the other hand, changes in the N-terminal 
region of the molecule were generally associated with 
complete loss of biological activity. However, biolo- 
gical effects of C-terminal fragments have also been 
described [19,20] and it therefore remains possible that 
the 1-19 and the l-30 amino acid molecules differ with 
respect o their biological activity. Future studies with 
synthetic peptides prepared according to the sequences 
reported here should provide answers to these questions 
and may also throw some light on the question of the 
physiological actions of human galanin(s) in humans. 
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